Financial Performance - The company's operating revenue for Q1 2025 was ¥2,429,825,335.81, a decrease of 1.81% compared to ¥2,474,697,457.66 in the same period last year[5] - Net profit attributable to shareholders was ¥112,095,257.24, down 20.99% from ¥141,879,437.62 year-on-year[5] - Basic and diluted earnings per share were both ¥0.15, representing a decline of 28.57% from ¥0.21 in the same period last year[5] - Total comprehensive income for the current period was 104,998,682.16, down from 146,079,426.17 in the previous period, a decrease of about 28.2%[20] - Net profit for the current period was 115,643,803.12, down from 145,264,098.40 in the previous period, representing a decrease of approximately 20.4%[19] Cash Flow and Operating Activities - The net cash flow from operating activities decreased by 77.87%, amounting to ¥8,425,190.10 compared to ¥38,063,364.43 in the previous year[5] - Cash flow from operating activities generated a net amount of 8,425,190.10, significantly lower than 38,063,364.43 in the previous period[21] - The decline in net cash flow from operating activities was attributed to an increase in the proportion of bank acceptance bill collections and a decrease in inventory changes compared to the previous year[8] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,269,855,861.11, an increase of 2.77% from ¥9,019,601,567.53 at the end of the previous year[5] - The total current assets increased to ¥3,999,396,150.59 from ¥3,726,840,162.91, reflecting a growth of about 7.3%[16] - Accounts receivable rose significantly to ¥1,200,307,190.06, up from ¥868,204,001.79, indicating an increase of approximately 38.2%[16] - The total liabilities increased to ¥3,879,907,761.23 from ¥3,802,101,150.19, marking a rise of about 2.0%[17] - The non-current liabilities decreased to ¥645,097,935.77 from ¥1,006,487,037.80, a reduction of approximately 35.9%[17] Shareholder Equity - Shareholders' equity attributable to the parent company increased by 3.28% to ¥5,155,519,978.65 from ¥4,991,588,524.78[5] - The total equity attributable to shareholders increased to ¥5,155,519,978.65 from ¥4,991,588,524.78, indicating a growth of approximately 3.3%[17] Expenses - Research and development expenses for the current period were 109,788,595.18, compared to 141,905,763.44 in the previous period, showing a reduction of approximately 22.6%[19] - The company reported a decrease in sales expenses from 291,064,033.27 in the previous period to 99,952,491.15 in the current period, a reduction of about 65.6%[19] - The company's total operating costs decreased from 2,328,929,009.30 to 2,299,988,387.70, a reduction of approximately 1.2%[19] Other Income and Changes - The company reported non-operating income of ¥7,067,182.83, primarily from government subsidies and asset disposal gains[7] - The company approved changes to accounting policies that are not expected to have a significant impact on the financial statements[13] - The company experienced an investment loss of 760,243.82 in the current period, compared to a gain of 1,188,728.16 in the previous period[19]
新华制药(000756) - 2025 Q1 - 季度财报